A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

NCT05424835 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Interventions

DRUG: SHR-A1811
DRUG: Pyrotinib in combination with Capecitabine.
DRUG: SHR-A1811

Sponsor

Jiangsu HengRui Medicine Co., Ltd.